MX2013001234A - Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a. - Google Patents

Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a.

Info

Publication number
MX2013001234A
MX2013001234A MX2013001234A MX2013001234A MX2013001234A MX 2013001234 A MX2013001234 A MX 2013001234A MX 2013001234 A MX2013001234 A MX 2013001234A MX 2013001234 A MX2013001234 A MX 2013001234A MX 2013001234 A MX2013001234 A MX 2013001234A
Authority
MX
Mexico
Prior art keywords
receptor agonists
derivatives
tandospirone
deuterated
ht1a receptor
Prior art date
Application number
MX2013001234A
Other languages
English (en)
Inventor
John Bondo Hansen
Mikael Soendergaard Thomsen
Original Assignee
Conrig Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conrig Pharma Aps filed Critical Conrig Pharma Aps
Publication of MX2013001234A publication Critical patent/MX2013001234A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

La presente invención se refiere a nuevos derivados de los agonistas del receptor 5-HIT1A de serotonina de la Fórmula I y en particular a composiciones y métodos para uso terapéutico.
MX2013001234A 2010-08-05 2011-08-04 Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a. MX2013001234A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201070349 2010-08-05
PCT/DK2011/050302 WO2012016569A1 (en) 2010-08-05 2011-08-04 Deuterated tandospirone derivatives as 5-ht1a receptor agonists

Publications (1)

Publication Number Publication Date
MX2013001234A true MX2013001234A (es) 2013-04-24

Family

ID=44512475

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001234A MX2013001234A (es) 2010-08-05 2011-08-04 Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a.

Country Status (5)

Country Link
US (1) US20130303497A1 (es)
EP (1) EP2601187A1 (es)
BR (1) BR112013002846A2 (es)
MX (1) MX2013001234A (es)
WO (1) WO2012016569A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013121440A1 (en) 2012-02-13 2013-08-22 Cadila Healthcare Limited Process for preparing benzisothiazol-3-yl-peperazin-l-yl-methyl-cyclo hexyl-methanisoindol-1,3-dione and its intermediates
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
IT201900000657A1 (it) 2019-01-16 2020-07-16 Procos Spa Processo per la sintesi di gepirone
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4507303A (en) 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
US5011841B1 (en) * 1989-11-14 1994-09-06 Pfizer Treatment of depression
US5330762A (en) 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
JP2002020291A (ja) 2000-06-30 2002-01-23 Sumitomo Pharmaceut Co Ltd 認知機能障害の治療剤
JP2003335678A (ja) 2002-05-17 2003-11-25 Sumitomo Pharmaceut Co Ltd 神経因性疼痛治療薬
US20040002500A1 (en) 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
JP4677191B2 (ja) 2004-02-16 2011-04-27 あすか製薬株式会社 過敏性腸症候群処置剤
EP1743645A4 (en) 2004-06-01 2012-11-14 Hisamitsu Pharmaceutical Co ADHESIVE PATCH
WO2008044336A1 (fr) 2006-10-11 2008-04-17 Hisamitsu Pharmaceutical Co., Inc. Préparation adhésive contenant un cristal
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension

Also Published As

Publication number Publication date
WO2012016569A1 (en) 2012-02-09
US20130303497A1 (en) 2013-11-14
EP2601187A1 (en) 2013-06-12
BR112013002846A2 (pt) 2016-06-07

Similar Documents

Publication Publication Date Title
MX2013001234A (es) Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a.
IN2014KN02601A (es)
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
IN2014MN02598A (es)
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
IN2014CN04530A (es)
IN2015DN01119A (es)
MX354102B (es) Derivados de bencimidazol-prolina.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
GEP20156372B (en) Pyridazinone compounds and their use as daao inhibitors
IN2014KN01075A (es)
MX2012013274A (es) Novedosos derivados de la pirimidina.
IN2012DN03182A (es)
IN2015DN01151A (es)
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX340033B (es) Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.
MX2013006420A (es) Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX350862B (es) Acidos de piperidinil naftilacetico.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal